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plasma glucose (FPG) were obtained. The deﬁnition of metabolic
syndrome encompasses three or more of the following abnor-
malities: WHR >0.9 in men and >0.85 in women, BMI 
>23kg/m2, BP >140/>90mmHg, FPG >110mg/dL, HDL 
<40mg/dL in men and <50mg/dL in women, FTG >150mg/dL.
RESULTS: Data were available in 686 Korean American sub-
jects, 62% females. The prevalence of metabolic syndrome in our
sample was 25%. Frequency of elevated BP, elevated TG, low
HDL, and FPG were 32%, 21%, 29%, and 12%, respectively. 
Overall obesity, measured by BMI, was 35% and centrally
obesity, measured by WHR, was 35%. When compared between
men and women, the prevalence of metabolic syndrome in 
men was 32% and 20% seen among the women (95% CI, 
0.061, 0.198; p < 0.001); increased central adiposity was similar
in both men (35%) and women (35%); and FPG was signiﬁ-
cantly elevated in men (18%) than in women 9% (95% CI,
0.035, 0.142; p = 0.001). CONCLUSION: Multiple metabolic
disorders are present in the Korean Americans. Early detection
and treatment of hypertension, dyslipidemia, obesity, and
glucose intolerance can prevent the progression of diabetes 
mellitus and CVD.
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OBJECTIVES: 1) To examine the differences in models of meta-
bolic syndrome developed using exploratory factor analysis
(EFA) versus conﬁrmatory factor analysis (CFA) in the Insulin
Resistance Atherosclerosis Study (IRAS) population; and 2) To
measure validity and reliability of the variables used to measure
each factor. METHODS: The subjects were from a previously
studied cohort of 1087 nondiabetic participants in the IRAS, a
study of the relationships among insulin resistance and cardio-
vascular disease risk factors. Data from this study were used to
test two hypothesized models. In the ﬁrst model, previously
developed using EFA, two latent factors were proposed: a
“hypertension factor;” and a “metabolic factor,” consisting of
variables measuring obesity, hyperlipidemia, and obesity status”.
The second hypothesized model consisted of four-factors (hyper-
tension, hyperlipidemia, insulin resistance, and obesity). A CFA
was performed testing the hypothesized models using EQS Mul-
tivariate Software Version 5.7b with maximum likelihood esti-
mation. Construct validity and reliability of the variables used
to measure the factors were then assessed in the model with best
ﬁt. RESULTS: The 4-factor model exhibited better ﬁt than the
2-factor model using criteria established by Hu and Bentler 
(chi-square = 377.3, df = 5). The ﬁnal four-factor model exhib-
ited a good ﬁt (CFI = 0.963, SRMR = 0.036, RMSEA = 0.077).
There were signiﬁcant intercorrelations between all the hypoth-
esized factors. A residual variance correlation was required
between the insulin sensitivity index variable and the fasting
glucose variable. All factors except the lipid factor (measured
using HDL and triglycerides) exhibited good values for construct
reliability and variance extracted. CONCLUSION: The results
of this analyses show that metabolic syndrome is best explained
by a four-factor model in the IRAS population, rather than the
previously described two-factor model that was developed using
EFA. The hyperlipidemia factor is not well deﬁned, and suggests
that additional variables may be required to adequately measure
this factor.
CARDIOVASCULAR DISEASE—Thrombosis Including
DVT
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OBJECTIVES: While effective in reducing the risk of venous
thromboembolism (VTE) following major orthopedic surgery
(MOS), antithrombotics can increase the risk of major bleeding.
We assessed impact of major bleeding following MOS on length
of stay (LOS) and inpatient charges. METHODS: Using a data-
base containing information on ~750,000 admissions annually
to 100+ US acute-care hospitals (MQProﬁle, Cardinal Informa-
tion Corp.), we identiﬁed all patients whom underwent MOS
between January 1, 1998 and December 13, 2000. Patients were
stratiﬁed according to whether or not they experienced major
postoperative bleeding prior to hospital discharge, deﬁned as: 
a) fatal bleeding; b) nonfatal bleeding at critical site; c) re-
operation due to bleeding; and d) overt bleeding with bleeding
index (BI) > 2, where BI = number of blood units transfused plus
pre-bleeding minus post-bleeding hemoglobin (g/dL) values. LOS
and inpatient charges were compared between patients with and
without major bleeding; ﬁndings were also examined for each of
the constituent measures of the composite endpoint. RESULTS:
A total of 23,518 patients were identiﬁed who underwent MOS;
2.6% experienced major bleeding (fatal bleeding, 0.1%; non-
fatal bleeding at a critical site, 0.2%; re-operation due to bleed-
ing, 0.7%; and overt bleeding associated with a BI > 2, 1.7%).
In multivariate analyses controlling for differences in baseline
characteristics between patients with and without major bleeds,
adjusted mean LOS was 1.8 days longer (95% CI: 1.5, 2.0)
among the former (6.1 days vs. 4.3 days for those without
bleeds); adjusted mean inpatient charges were $7593 higher
(95% CI: $6622, $8646) ($25,669 vs. $18,076). CONCLU-
SION: Major bleeding following MOS signiﬁcantly increases
LOS and hospital charges. Small absolute increases in the risk of
major bleeding may translate into additional costs of inpatient
care that counterbalance cost savings associated with VTE events
averted. Cost of major bleeding following MOS should factor
into choice of VTE prophylaxis.
PCV58
CLINICAL AND ECONOMIC ISSUES IN THE PREVENTION OF
VENOUS THROMBOEMBOLISM IN HOSPITALIZED
ORTHOPEDIC PATIENTS: ENOXAPARIN VERSUS WARFARIN
Balu S1,Vogenberg FR2, Lichtig L2, O’Connor P2
1Purdue University, West Lafayette, IN, USA; 2Aon Consulting Life
Sciences Practice, Wellesley, MA, USA
OBJECTIVES: Current American College of Chest Physicians’
guidelines recommend Venous Thromboembolism (VTE) pro-
phylaxis for orthopedic patients. This study examines prophy-
lactic therapy received by hospitalized orthopedic patients, rate
of secondary diagnosis of VTE, and compares overall hospital
costs by major cost-centers among enoxaparin and warfarin-
treated patients in order to rationalize drug use. METHODS: An
administrative database of 720,982 discharges containing ICD-
9-CM coding and other data from hospitals across the U.S. was
analyzed. Study patients were those whom underwent hip or
knee replacement procedures, and were prescribed warfarin or
enoxaparin. Length of stay (LOS), age, gender, number of diag-
noses (ND), and in-hospital deaths were compared between 
warfarin and enoxaparin cohorts using independent t-tests 
and chi-squared analysis. Least-squares regression was used to
